{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:50:49Z","timestamp":1793501449398,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Intratumoral delivery of NBTXR3 radioenhancer followed by radiation therapy (RT) previously demonstrated safety and feasibility in cisplatin-ineligible and cetuximab-ineligible patients with locally advanced head and neck squamous cell carcinoma (HNSCC) in a dose-escalation phase 1 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate safety and preliminary efficacy of NBTXR3 followed by RT in patients with locally advanced HNSCC ineligible to receive concurrent systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      This single-arm, phase 1 dose-expansion nonrandomized clinical trial was conducted across 20 centers in Europe between March 4, 2019, and January 10, 2022. Patients were ineligible for cisplatin and cetuximab per investigator\u2019s judgement and had unresectable T3-4 or overall stage III\/IVA HNSCC (per the\n                      <jats:italic>American Joint Committee on Cancer Staging Manual<\/jats:italic>\n                      ,\n                      <jats:italic>eighth edition<\/jats:italic>\n                      ) of the oral cavity or oropharynx. Data were analyzed from July to August 2023.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients received a single intratumoral administration of NBTXR3 in the primary tumor at the recommended dose of 22% of estimated tumor volume (ETV) followed by RT (70 Gy over 35 fractions).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Primary outcomes were safety and efficacy assessed by the objective response rate (ORR) of the NBTXR3-injected primary tumor. Other outcomes included ORR of all lesions (injected primary tumor and noninjected involved lymph nodes), progression-free survival, and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 56 patients treated, the median (range) age was 72 (44-89) years, 40 (71%) were men, 34 (61%) were 70 years and older, and 36 (64%) had a substantial burden of comorbidities (age-adjusted Charlson Comorbidity Index score of 4 or greater). Median (range) follow-up was 33.0 (0.7-44.6) months. NBTXR3-related treatment-emergent adverse events occurred in 9 patients (16%), of which 6 (11%) were grade 3 or higher, the most frequent being stomatitis (2 [4%]). Objective tumor response was assessed in 44 patients, as 12 patients were unable to complete RT or did not have posttreatment tumor assessment. In this evaluable patient population, the ORR of the injected primary tumor and ORR of all lesions were 82% (95% CI, 67-92) and 80% (95% CI, 65-90), respectively. Among all 56 treated patients, the median progression-free survival was 11.4 months (95% CI, 6.7 to not reached), and the median overall survival was 18.1 months (95% CI, 9.7 to not reached).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This dose-expansion phase 1 nonrandomized clinical trial demonstrated that intratumoral NBTXR3 followed by RT in a high-risk patient population unable to receive cisplatin or cetuximab was feasible and had a preliminary efficacy signal that supports a benefit-risk profile being evaluated in an ongoing randomized phase III trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT01946867\">NCT01946867<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2025.4939","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:30:32Z","timestamp":1769704232000},"page":"284","source":"Crossref","is-referenced-by-count":11,"title":["Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer"],"prefix":"10.1001","volume":"152","author":[{"given":"Christophe","family":"Le Tourneau","sequence":"first","affiliation":[{"name":"Department of Therapeutic Innovation and Early Trials (DITEP), Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Liem","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy-Brachytherapy, Oscar Lambret Cancer Center, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Deraedt","sequence":"additional","affiliation":[{"name":"Departement of Head and Neck Surgery, Oscar Lambret Cancer Center, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Salas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AMU, Assistance Publique\u2013Hopitaux de Marseille (AP-HM), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Calugaru","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Plana","family":"Serrahima","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Catal\u00e0 d\u2019Oncologia (ICO-Hospitalet), IDIBELL, Hospitalet de Llobregat, Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Wong Hee Kam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AMU, Assistance Publique\u2013Hopitaux de Marseille (AP-HM), Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Curie, Paris, France"},{"name":"NU-MED CDiTO Tomaszow Mazowiecki, Tomasz\u00f3w Mazowiecki, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lesnik","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Poissonnet","sequence":"additional","affiliation":[{"name":"Department of ENT Surgery, Institut Universitaire de la Face et du Cou, Centre Antoine-Lacassagne, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bozec","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Antoine Lacassagne-Institut Universitaire, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma","family":"Saada-Bouzid","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Antoine Lacassagne; Laboratory of Translational Research in Oncology, Cote d\u2019Azur University, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"J\u00e9goux","sequence":"additional","affiliation":[{"name":"Head and Neck Department, University Hospital, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Univ Rennes, CLCC Eug\u00e8ne Marquis, INSERM, LTSI-UMR, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Devisetty","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Lelonge","sequence":"additional","affiliation":[{"name":"ENT-Head and Neck Surgery Service, Saint-\u00c9tienne University Hospital Center, Saint-Priest-en-Jarez, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jadaud","sequence":"additional","affiliation":[{"name":"Radiation Department, Saint-\u00c9tienne University Hospital Center, Saint-Priest-en-Jarez, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Houdas","sequence":"additional","affiliation":[{"name":"Nanobiotix, SA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Debard","sequence":"additional","affiliation":[{"name":"Nanobiotix, SA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar I.","family":"Vivar","sequence":"additional","affiliation":[{"name":"Nanobiotix, SA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Finzi","sequence":"additional","affiliation":[{"name":"Nanobiotix, SA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Serra","sequence":"additional","affiliation":[{"name":"MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom"},{"name":"Department of Statistical Methodology, Saryga, Tournus, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Linares","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut Catal\u00e0 d\u2019Oncologia (ICO), Radiobiology and Cancer Group, ONCOBELL Program, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Arranz Obispo","sequence":"additional","affiliation":[{"name":"Department of Maxillofacial and Oral Surgery, Bellvitge University Hospital (HUB), Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Thariat","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fran\u00e7ois Baclesse Center, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rambeau","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, UCP VADS, Centre Fran\u00e7ois Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fakhry","sequence":"additional","affiliation":[{"name":"Department of Oto-Rhino-Laryngology Head and Neck Surgery, La Conception University Hospital, AP-HM, Aix Marseille Univ, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Oto-Rhino-Laryngology Head and Neck Surgery, La Conception University Hospital, AP-HM, Aix Marseille Univ, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Giralt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bra\u00f1a Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel S\u00e1ez","family":"Barba","sequence":"additional","affiliation":[{"name":"Maxillofacial Surgery Service, Vall d\u2019Hebron University Hospital, Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gorphe","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Institute Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frigyes","family":"Helfferich","sequence":"additional","affiliation":[{"name":"Medical Center, Hungarian Defense Forces, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Herczeg","sequence":"additional","affiliation":[{"name":"Center of Radiotherapy and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Papai","sequence":"additional","affiliation":[{"name":"Medical Center, Hungarian Defense Forces, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Fijuth","sequence":"additional","affiliation":[{"name":"Departement of Head and Neck Surgery, Oscar Lambret Cancer Center, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Tak\u00e1csi-Nagy","sequence":"additional","affiliation":[{"name":"Center of Radiotherapy and National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary"},{"name":"Department of Oncology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"ooi250090r1","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"ooi250090r2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5603\/RPOR.a2021.0002","article-title":"Radiotherapy for locally advanced head and neck cancer in elderly patients: results and prognostic factors a single cohort.","volume":"26","author":"Viani","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"issue":"3","key":"ooi250090r3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11864-023-01051-w","article-title":"Treatment considerations for patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin.","volume":"24","author":"Kim","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"ooi250090r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102585","article-title":"Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: is there a standard of care?","volume":"119","author":"Haddad","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"ooi250090r5","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3389\/fonc.2019.01522","article-title":"Treating patients with locally advanced squamous cell carcinoma of the head and neck unsuitable to receive cisplatin-based therapy.","volume":"9","author":"Porceddu","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"ooi250090r6","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.3390\/cancers14112809","article-title":"Management of older adults with locally advanced head and neck cancer.","volume":"14","author":"Dickstein","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ooi250090r7","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1002\/cam4.882","article-title":"Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, Germany.","volume":"5","author":"G\u00f6llnitz","year":"2016","journal-title":"Cancer Med"},{"issue":"13","key":"ooi250090r8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1200\/JCO.22.02350","article-title":"Good radiosensitizer hunting.","volume":"41","author":"Mell","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"ooi250090r9","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.22.00980","article-title":"Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation.","volume":"41","author":"Patil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"ooi250090r10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1634\/theoncologist.2013-0325","article-title":"Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy.","volume":"20","author":"Moye","year":"2015","journal-title":"Oncologist"},{"issue":"10","key":"ooi250090r11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/cncr.29956","article-title":"Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.","volume":"122","author":"Amini","year":"2016","journal-title":"Cancer"},{"key":"ooi250090r12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.617184","article-title":"The impact of comorbidity on survival in patients with head and neck squamous cell carcinoma: a nationwide case-control study spanning 35 years.","volume":"10","author":"Ruud Kj\u00e6r","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"ooi250090r13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/cancers12020258","article-title":"Outcomes for elderly patients aged 70 to 80 years or older with locally advanced oral cavity squamous cell carcinoma: a propensity score-matched, nationwide, oldest old patient-based cohort study.","volume":"12","author":"Shia","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ooi250090r14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/jamaoncol.2017.0973","article-title":"Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques.","volume":"3","author":"Leeman","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"ooi250090r15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamaoto.2022.0890","article-title":"Comparison of patients with head and neck cancer in randomized clinical trials and clinical practice: a systematic review.","volume":"148","author":"Kaanders","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"ooi250090r16","first-page":"443","article-title":"New use of metals as nanosized radioenhancers.","volume":"34","author":"Pottier","year":"2014","journal-title":"Anticancer Res"},{"issue":"9","key":"ooi250090r17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2217\/fon.12.96","article-title":"Nanoscale radiotherapy with hafnium oxide nanoparticles.","volume":"8","author":"Maggiorella","year":"2012","journal-title":"Future Oncol"},{"key":"ooi250090r18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1748-717X-9-150","article-title":"Hafnium oxide nanoparticles: toward an in vitro predictive biological effect?","volume":"9","author":"Marill","year":"2014","journal-title":"Radiat Oncol"},{"issue":"8","key":"ooi250090r19","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"ooi250090r20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hed.27739","article-title":"International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.","volume":"46","author":"Liem","year":"2024","journal-title":"Head Neck"},{"key":"ooi250090r21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2021.01.007","article-title":"Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx.","volume":"146","author":"Hoffmann","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"ooi250090r22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","article-title":"First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas.","volume":"23","author":"Bonvalot","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ooi250090r23","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.3390\/diagnostics12092156","article-title":"Imaging features of intratumoral injection of NBTXR3 for head and neck squamous cell carcinoma lymph node metastases.","volume":"12","author":"Ginat","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"ooi250090r24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"ooi250090r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8175","article-title":"Comparison of duration of response vs conventional response rates and progression-free survival as efficacy end points in simulated immuno-oncology clinical trials.","volume":"4","author":"Hu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"ooi250090r26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"ooi250090r27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"key":"ooi250090r29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2020.09.008","article-title":"Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).","volume":"141","author":"Tao","year":"2020","journal-title":"Eur J Cancer"},{"key":"ooi250090r30","doi-asserted-by":"publisher","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial.","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"ooi250090r31","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial.","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"ooi250090r32","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1470-2045(23)00265-6","article-title":"Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.","volume":"24","author":"Nutting","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"ooi250090r33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s42399-023-01562-5","article-title":"Clinical efficacy and complications of intensity-modulated radiation therapy in patients with oropharyngeal carcinoma: especially focus on osteoradionecrosis.","volume":"5","author":"Hiramine","year":"2023","journal-title":"SN Compr Clin Med"},{"issue":"11","key":"ooi250090r34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41538","article-title":"Toxicity profiles and survival outcomes among patients with nonmetastatic oropharyngeal carcinoma treated with intensity-modulated proton therapy vs intensity-modulated radiation therapy.","volume":"5","author":"Youssef","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"11","key":"ooi250090r35","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/hed.25352","article-title":"Early (90-day) mortality after radical radiotherapy for head and neck squamous cell carcinoma: a population-based analysis.","volume":"40","author":"Hamilton","year":"2018","journal-title":"Head Neck"},{"key":"ooi250090r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100725","article-title":"Nomogram to predict risk of early mortality following definitive or adjuvant radiation and systemic therapy for head and neck cancer.","volume":"45","author":"Raab","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"ooi250090r37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"issue":"12","key":"ooi250090r38","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/14796694.2025.2496131","article-title":"Nanoray-312: phase III study of NBTXR3 + radiotherapy \u00b1 cetuximab in elderly, platinum-ineligible locally advanced HNSCC.","volume":"21","author":"Le Tourneau","year":"2025","journal-title":"Future Oncol"},{"issue":"9","key":"ooi250090r39","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/hed.25200","article-title":"Age-adjusted comorbidity and survival in locally advanced laryngeal cancer.","volume":"40","author":"Mulcahy","year":"2018","journal-title":"Head Neck"},{"key":"ooi250090r28","unstructured":"US Food and Drug Administration. Inclusion of older adults in cancer clinical trials: guidance for industry. Accessed February 7, 2025. https:\/\/www.fda.gov\/media\/156616\/download"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2844257\/jamaotolaryngology_le_tourneau_2026_oi_250090_1771965315.68559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:00:29Z","timestamp":1773327629000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2844257"}},"subtitle":["A Phase 1 Dose-Expansion Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.4939","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}